top of page

The Company

Novapep is an Australian-US biotech company which has developed its Biparetide agonist peptide structure, which mimics the mechanisms of action of Activated Protein C ('APC'). APC and Biparetide activate PAR1 and PAR3 cell receptors, which produces anti-inflammatory and cytoprotective cell signalling.  The Company’s primary target diseases inflammatory bowel disease ('IBD') and sepsis.

 

Novapep’s co-founders, Professor John Griffin at the Scripps Research Institute in San Diego and Professor Chris Jackson at the University of Sydney, have conducted over 15 years of ground-breaking R&D in APC.  Professor Griffin invented the PAR1 agonist peptide and subsequently Biparetide - the PAR1/PAR3 conjugated agonist peptide.

 

Novapep has licensed the Biparetide patents from the Scripps, which provide IP protection to 2039 and Novapep is currently pursuing formulation patents

​

The competitive advantages of Biparetide include:

  • Biparetide far cheaper to manufacture than APC, is stable and is well suited to systemic and oral delivery methods.

 

  • Current treatments for these disease have significant side effects and/or are far more expensive to manufacture                than biparetide formulations.

​​

  • Biparetide exerts multiple protective mechanisms of action in target diseases.

​​

  • Successful translation of Biparetide formulations will make them first in class drugs for Novapep's target indications.

bottom of page